Get the Stockscreener App
113.56
0.11%
-0.13
After Hours:
113.50
-0.06
-0.05%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Merck Co Inc stock is traded at $113.56, with a volume of 9.53M.
It is down -0.11% in the last 24 hours and down -4.13% over the past month.
See More
Previous Close:
$113.69
Open:
$113.61
24h Volume:
9.53M
Relative Volume:
1.01
Market Cap:
$285.14B
Revenue:
$62.48B
Net Income/Loss:
$13.74B
P/E Ratio:
63.09
EPS:
1.8
Net Cash Flow:
$13.15B
1W Performance:
-1.79%
1M Performance:
-4.13%
6M Performance:
-13.94%
1Y Performance:
+10.31%
1-Day Range:
$112.70
$114.01
1-Week Range:
$112.70
$116.26
52-Week Range:
$99.14
$134.63
Merck Co Inc Stock (MRK) Company Profile
Name
Merck Co Inc
Sector
Industry
Phone
908-740-4000
Address
2000 GALLOPING HILL ROAD, KENILWORTH, NJ
Merck Co Inc Stock (MRK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-11-24 | Downgrade | Societe Generale | Hold → Sell |
| Jan-04-24 | Upgrade | TD Cowen | Market Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Buy |
| Oct-27-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Oct-20-23 | Upgrade | UBS | Neutral → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Hold |
| Apr-13-23 | Upgrade | Citigroup | Neutral → Buy |
| Mar-28-23 | Downgrade | Societe Generale | Buy → Hold |
| Mar-13-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-06-23 | Initiated | Jefferies | Buy |
| Feb-22-23 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-04-23 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Oct-10-22 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-14-22 | Upgrade | Berenberg | Hold → Buy |
| Jul-06-22 | Upgrade | Daiwa Securities | Neutral → Buy |
| Jun-06-22 | Resumed | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-16-21 | Initiated | Daiwa Securities | Neutral |
| Dec-13-21 | Downgrade | UBS | Buy → Neutral |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Dec-07-21 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-29-21 | Downgrade | Citigroup | Buy → Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-01-21 | Upgrade | Argus | Hold → Buy |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-27-21 | Resumed | Truist | Buy |
| May-20-21 | Downgrade | Argus | Buy → Hold |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Aug-03-20 | Upgrade | Goldman | Neutral → Buy |
| Jun-12-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-16-19 | Initiated | SVB Leerink | Outperform |
| Jul-03-19 | Initiated | Mizuho | Buy |
| May-28-19 | Initiated | Goldman | Neutral |
| May-13-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-16-18 | Reiterated | Citigroup | Buy |
| Oct-09-18 | Resumed | Guggenheim | Buy |
| Apr-23-18 | Upgrade | Goldman | Neutral → Buy |
| Apr-17-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-05-18 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-12-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Feb-14-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-07-18 | Reiterated | Morgan Stanley | Equal-Weight |
| Jan-16-18 | Upgrade | SunTrust | Hold → Buy |
View All
Merck Co Inc Stock (MRK) Latest News
Merck & Co., Inc. (NYSE:MRK) Trading Down 0.1% - MarketBeat
Merck & Co. Inc. (MRK): A Strong Investment as KEYTRUDA Sales Drive Revenue Growth - Insider Monkey
Merck & Co. Inc. (MRK): A Strong Investment as KEYTRUDA Sales Drive Revenue Growth - Yahoo Finance
B. Riley Wealth Advisors Inc. Sells 14,516 Shares of Merck & Co., Inc. (NYSE:MRK) - MarketBeat
Merck & Co., Inc. (MRK) Projects 21% Upside with $140 Price Target as Keytruda and New Vaccines Drive Growth - Insider Monkey
Merck & Co., Inc. (MRK) Projects 21% Upside with $140 Price Target as Keytruda and New Vaccines Drive Growth - Yahoo Finance
Merck & Co., Inc. (NYSE:MRK) is a favorite amongst institutional investors who own 79% - Yahoo Finance
NewEdge Advisors LLC Raises Stock Holdings in Merck & Co., Inc. (NYSE:MRK) - MarketBeat
Merck & Co., Inc. (NYSE:MRK) Shares Sold by Buck Wealth Strategies LLC - MarketBeat
Is Merck Stock a Buy? - The Motley Fool
Susquehanna Portfolio Strategies LLC Has $41.69 Million Stock Holdings in Merck & Co., Inc. (NYSE:MRK) - MarketBeat
Merck & Co., Inc. (NYSE:MRK) Shares Up 0.6% - MarketBeat
Merck & Co. Inc. stock outperforms competitors on strong trading day - MarketWatch
Merck's Wide Moat Is Supported by Leading Oncology Drug Keytruda and a Growing Pipeline - Morningstar
Q2 2026 Earnings Forecast for Merck & Co., Inc. Issued By Zacks Research (NYSE:MRK) - MarketBeat
Merck & Co., Inc. (MRK): An Undervalued Wide Moat Stock to Buy According to Analysts - Yahoo Finance
Merck & Co. Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Is Merck & Co., Inc. (MRK) the Best Cheap Beginner Stock to Invest In? - Insider Monkey
Is Merck & Co., Inc. (MRK) the Best Cheap Beginner Stock to Invest In? - Yahoo Finance
Evaxion Biotech Partners With Merck To Expand Vaccine Development - Benzinga
Fred Alger Management LLC Acquires 23,589 Shares of Merck & Co., Inc. (NYSE:MRK) - MarketBeat
Merck & Co. Inc. (MRK): A Good Undervalued Blue Chip Stock to Buy According to Analysts - Yahoo Finance
Merck & Co. Inc. stock outperforms competitors despite losses on the day - MarketWatch
Merck's colorectal cancer therapy fails late-stage trial - Reuters
FDA Casts Doubt On Use Of Merck, Bristol Myers' PD-1 Cancer Drugs For Certain Type Of Gastric Cancer Patients - Yahoo Finance
Merck & Co., Inc. (NYSE:MRK) Shares Up 0.5% - MarketBeat
Merck's Experimental Favezelimab/Keytruda Combo Fails In Late-Stage Colorectal Cancer Study - Yahoo Finance
Merck: trial failure in colorectal cancer - Marketscreener.com
Merck: three new indications for Keytruda in Japan - Marketscreener.com
Merck fails in late-stage trial for Keytruda combo in colon cancer - Seeking Alpha
Merck's colorectal cancer therapy fails late-stage trial - Marketscreener.com
Wescott Financial Advisory Group LLC Has $20.62 Million Position in Merck & Co., Inc. (NYSE:MRK) - MarketBeat
Anti-retroviral Drugs Market to hit USD 42.5 billion by 2032, says Global Market Insights Inc. - GlobeNewswire Inc.
Merck Animal Health Announces Expansion of NOBIVAC® NXT Platform with the First and Only RNA-Particle Technology Vaccine for Feline Leukemia Virus - BioSpace
Merck & Co., Inc. (MRK) Poised for 20% Gain, Analysts Say - Insider Monkey
Merck & Co., Inc. (MRK) Poised for 20% Gain, Analysts Say - Yahoo Finance
Merck & Co. Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
NXT Platform with the First and Only RNA-Particle Technology Vaccine for Feline Leukemia Virus - Business Wire
BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp Raises Holdings in Merck & Co., Inc. (NYSE:MRK) - MarketBeat
Possible Bearish Signals With Merck Insiders Disposing Stock - Yahoo Finance
13 Most Undervalued Blue Chip Stocks To Buy According To Analysts - Insider Monkey
Merck & Co., Inc. (NYSE:MRK) Trading Down 0.7% - MarketBeat
Morse Asset Management Inc Raises Position in Merck & Co., Inc. (NYSE:MRK) - MarketBeat
Who Are Pfizer's (PFE) Main Competitors? - Investopedia
Merck & Co., Inc. (NYSE:MRK) Stock Position Lifted by Edge Capital Group LLC - MarketBeat
Court revives more than 500 lawsuits over Fosamax femur fracture risk - Reuters
Merck & Co., Inc. (NYSE:MRK) Shares Down 0.2% - MarketBeat
SEC settles insider charges related to Merck-Pandion merger - BioWorld Online
Is Recursion Pharmaceuticals Stock a Buy? - The Motley Fool
Merck & Co., Inc. (NYSE:MRK) Stock Holdings Boosted by Bridges Investment Management Inc. - MarketBeat
Is It Too Late to Buy ServiceNow Stock? - The Motley Fool
Merck Co Inc Stock (MRK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Merck Co Inc Stock (MRK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Guindo Chirfi | Chief Marketing Officer |
Aug 05 '24 |
Option Exercise |
115.20 |
36,901 |
4,250,995 |
57,782 |
| Smart Dalton | SVP Fin. - Global Controller |
May 03 '24 |
Option Exercise |
128.26 |
2,046 |
262,420 |
4,708 |
| Smart Dalton | SVP Fin. - Global Controller |
May 04 '24 |
Option Exercise |
127.51 |
612 |
78,036 |
4,730 |
| DeLuca Richard R. | EVP&Pres, Merck Animal Heallth |
May 04 '24 |
Option Exercise |
127.51 |
27,126 |
3,458,836 |
163,720 |
| Klobuchar Michael A | EVP - Chief Strategy Officer |
May 04 '24 |
Option Exercise |
127.51 |
887 |
113,101 |
24,058 |
| Oosthuizen Johannes Jacobus | President, U.S. Market |
May 04 '24 |
Option Exercise |
127.51 |
912 |
116,289 |
24,271 |
| Romanelli Joseph | President, Human Health Int?l |
May 02 '24 |
Option Exercise |
128.80 |
2,262 |
291,346 |
21,831 |
| Smart Dalton | SVP Fin. - Global Controller |
May 02 '24 |
Option Exercise |
128.80 |
381 |
49,073 |
3,048 |
| Merck & Co., Inc. | 10% Owner |
Mar 11 '24 |
Buy |
23.00 |
21,397,205 |
492,135,715 |
1,000 |
| Litchfield Caroline | EVP & CFO |
Feb 14 '24 |
Option Exercise |
58.08 |
38,291 |
2,223,941 |
89,199 |
0.51%
1.38%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):